"I CAN'T KEEP DOING THIS": Doctor pleads for review of data during COVID-19 Senate hearing

https://www.youtube.com/watch?v=Tq8SXOBy-4w

COVID-19

Ivermectin has antiviral effects against several distinct positive-sense single-strand RNA viruses, including SARS-CoV-2.^[79] On 10 April 2020, the FDA issued guidance to not use veterinary-grade ivermectin as treatment for COVID-19 in humans.^[80][81]

Ivermectin inhibits replication of SARS-CoV-2 in monkey kidney cell culture with an IC₅₀ of 2.2 - 2.8 µM, making it a possible candidate for COVID-19 drug repurposing research.^[82][83] The doses used in cell culture would require 10⁴ larger doses in humans based on this data, which does not look promising as an effective treatment for COVID-19.^[84][85] Such high doses of ivermectin are not covered by the current human-use approvals of the drug and could be dangerous, as the likely antiviral mechanism of action is the suppression of a host cellular process,^[85] specifically the inhibition of nuclear transport by importin α/β1.^[86]

A preprint published in April 2020 claimed benefits of ivermectin in the treatment of COVID-19, but it was a retrospective study based on questionable hospital data from Surgisphere and was withdrawn at the end of May. The preprint led to several government agencies in Latin America recommending ivermectin as a COVID-19 treatment; these recommendations were later denounced by the regional WHO office.^[87] On October 12, 2020 Peru withdrew its authorization to use ivermectin and hydroxychloroquine as COVID-19.^[88]

In November 2020 a meta-analysis found only weak evidence of benefit.^[89] The World Health Organization and National Institute of Health abandoned trials of ivermectin for use treating COVID-19, because of a lack of promising evidence.^[90]

https://en.wikipedia.org/wiki/Ivermectin

Ivermectin has been shown to inhibit the replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in cell cultures.7 However, pharmacokinetic and pharmacodynamic studies suggest that achieving the plasma concentrations necessary for the antiviral efficacy detected in vitro would require administration of doses up to 100-fold higher than those approved for use in humans.8,9  

https://www.covid19treatmentguidelines.nih.gov/antiviral-therapy/ivermectin/

https://www.healio.com/news/primary-care/20201208/this-was-a-gift-to-us-ivermectin-effective-for-covid19-prophylaxis-treatment

https://apnews.com/article/fact-checking-afs:Content:9768999400

One study published on Dec. 2 in the International Journal of Infectious Diseases found that a five-day course of ivermectin was found to be safe and effective in treating mild COVID-19 adult patients. The trial involved 72 hospitalized patients in Bangladesh, and researchers said larger trials are needed to confirm the preliminary findings.

Another large study, published in November as a preprint, found the addition of ivermectin to standard care to be a "very effective drug for treatment of COVID-19 patients with significant reduction in mortality compared to hydroxychloroquine plus standard treatment only."

https://www.fox5ny.com/news/doctor-pleads-for-review-of-data-on-ivermectin-as-covid-19-treatment-during-senate-hearing